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Summary
Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle
cell lymphoma (MCL) and clinical trial data supports use at second line
compared to later relapse. We aimed to investigate outcomes and tolerabil-
ity for ibrutinib when given second line in a real-world setting. Our multi-
centre retrospective analysis included 211 R/R MCL patients, median age
73 years, receiving ibrutinib second-line within the United Kingdom’s
National Health Service. Overall response to ibrutinib was 69% (complete
response 27%). The median progression-free survival (PFS) was
178 months (95% CI 131–222) and median overall survival (OS)
239 months (95% CI 150–328). Drug-related adverse event led to dose
reduction in 10% of patients and discontinuation in 5%. In patients with
progressive disease, accounting for 100 of 152 patients stopping ibrutinib,
43% received further systemic therapy. Post-ibrutinib rituximab, ben-
damustine and cytarabine (R-BAC) showed a trend toward improved sur-
vival compared to alternative systemic treatments (post-ibrutinib median
OS 140 months, 95% CI 81–198, vs. 36 months, 95% CI 26–45,
P = 006). Our study confirms the clinical benefit and good tolerability of
ibrutinib at first relapse in a real-world population. Patients progressing on
ibrutinib had limited survival but outcomes with R-BAC in select patients
were promising.
Keywords: ibrutinib, mantle cell lymphoma, post-ibrutinib outcomes, clini-
cal aspects.
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Introduction
Mantle cell lymphoma (MCL) is a rare subtype of non-
Hodgkin lymphoma which most commonly presents in older
age and tends to follow an aggressive, multiply relapsing clin-
ical course. Over the past 20 years therapeutic advances,
including the emergence of several novel agents, have led to
improved survival for MCL patients.1,2 A crucial develop-
ment has been ibrutinib, a first in class once a day Bruton0s
tyrosine kinase (BTK) inhibitor that demonstrated impressive
response rates and a favourable side-effect profile in heavily
pre-treated patients.3
Ibrutinib is now widely available as a treatment option in
the relapsed, refractory setting but there remains no consensus
on optimal timing within the treatment algorithm.4 A pooled
analysis of patients treated with ibrutinib in three clinical trials
highlighted a significant benefit in progression-free survival
(PFS) and overall survival (OS) for patients receiving ibrutinib
at first relapse compared to those treated at later relapse (me-
dian PFS 254 months versus (vs.) 103 months) suggesting
earlier use is most beneficial.5–7 However, general applicability
of trial findings to real-world populations enriched with frailer
patients prone to drug toxicity is unknown, and uncertainties
persist regarding post-ibrutinib outcomes. The largest study to
date reported a median post-ibrutinib OS of only 58 months,
although this may simply reflect a patient group where multi-
ply-relapsed disease and short-lived responses to ibrutinib
were common.8
Ibrutinib for relapsed MCL was made available on the
National Health Service (NHS) in March 2015 for patients in
England via the Cancer Drugs Fund. In January 2018, follow-
ing National Institute for Health and Care Excellence (NICE)
appraisal, reimbursement was approved in all United King-
dom (UK) patients if they had received only one previous
line of therapy, effectively making this standard of care in
the UK.9
In this retrospective cohort study, we have compiled and
evaluated data on 211 patients with MCL receiving ibrutinib
at first relapse treated on the NHS in the UK. We aimed to
investigate PFS and OS benefit in a real-world patient group
and provide insights on drug tolerability and survival out-
comes following ibrutinib discontinuation. This is the first
time post-ibrutinib outcomes have been reported in patients
exclusively receiving treatment at first relapse.
Method
Centres across the UK were invited to contribute anonymised
data to an NHS service evaluation (patient selection in Fig-
ure S1). To meet eligibility patients had to have relapsed or
refractory MCL, received only one prior line of systemic
therapy (excluding steroids or radiotherapy) and received at
least 1 day of ibrutinib, which was commenced no earlier
than 15th March 2015, when ibrutinib first became available
on the NHS for this indication, and no later than 30th June
2019. Centres were asked to submit data for all patients
meeting eligibility criteria treated at their institution with
any exceptions recorded. The database was locked in June
2020 for analysis.
Medical records were evaluated for clinical characteristics,
pathology and radiology data and therapies used pre- and
post-ibrutinib. Clinicians were asked to provide response and
progression data according to Lugano classification.10 Use of
computer topography (CT) and positron emission topogra-
phy (PET)/CT varied between institutions and bone marrow
biopsy was not routinely performed to assess response mean-
ing complete response is denoted by CR/CRu (complete
response unconfirmed). Due to retrospective methodology,
adverse events whilst on therapy were not graded and report-
ing was limited to episodes that required dose reduction or
permanent cessation of ibrutinib.
PFS was defined as the time from day 1 of ibrutinib ther-
apy until investigator assessed progression or death from any
cause (event) or last date of clinical review with no evidence
of progression (no event). Patients consolidated with allo-
geneic stem cell transplant were not censored at date of
transplant. Overall survival was defined as the time from day
1 of ibrutinib therapy until death from any cause. Post-ibru-
tinib OS was defined as the date of cessation of ibrutinib
until death from any cause, as previously adopted by Martin
et al.8
Kaplan-Meier survival analyses, Cox regression and log-
rank tests were used for time to event analyses. The propor-
tional hazard assumption for each covariable was tested by
time-dependent Cox model. Baseline characteristics of
patients progressing on ibrutinib were stratified according to
post-ibrutinib management and compared using logistic
regression. Statistical analyses were performed in IBM SPSS
Statistics for Windows version 24 (IBM Corp., Armonk, NY,
USA).
The prespecified primary objective was PFS, secondary
objectives included OS, incidence of ibrutinib discontinua-
tion due to toxicity, incidence of ibrutinib dose reduction
due to toxicity and OS after ibrutinib discontinuation for
patients with progressive disease.
All patient data were anonymised at source and treated
according to the principles of the declaration of Helsinki and
the UK Data Protection Act (1998).
Results
Baseline patient characteristics
Patient data were returned on 211 eligible patients from 38
centres, including 14 academic sites and 24 district general
hospitals (DGHs). The median age of patients at the start of
ibrutinib was 73 years (range: 33–96), 70% were male. When
starting ibrutinib the Eastern Cooperative Oncology Group
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(ECOG) performance status (PS) was 0–1 in 76% (147/193)
and 2–4 in 24% (46/193); Simplified Mantle cell lymphoma
international prognostic index (sMIPI) group was low in
13% (19/142), intermediate in 41% (58/142) and high in
46% (65/142); 4% (8/211) had central nervous system (CNS)
involvement. All patients received only one prior line of sys-
temic therapy. Twenty-eight percent (60/211) received high-
dose cytarabine based frontline therapy and 25% (53/211)
had consolidation with haematopoietic stem cell transplant
(HSCT). For comprehensive baseline characteristics see
Table I.
Median PFS with frontline therapy was 214 months (95%
CI 155–274). Fifty-two percent (109/211) had progression
of disease within 24 months of treatment (early POD),
including 38 patients (18%) with primary refractory disease.
Response rates and survival analysis
The overall response rate (ORR) to ibrutinib in evaluated
patients was 69% (124/179) with complete response (CR/CRu)
27% (49/179) and partial response (PR) 42% (75/179). Of 32
patients without response data available 28 patients (88%)
remained on ibrutinib after 6 months. At data-lock median
follow-up of survivors by reverse censoring was 24 months
(range 9–61 months), 118 patients had died, 59 remained on
ibrutinib and 32 were alive having stopped ibrutinib (reasons:
progressive disease [n = 17], allogeneic (allo) HSCT [n = 10],
drug toxicity [n = 4], patient choice [n = 1]).
The median PFS was 178 months (95% CI 131–222)
and the median OS was 239 months (95% CI 150–328)
(Fig 1). PFS with ibrutinib exceeded PFS with frontline ther-
apy in 40% (68/170) of evaluable patients. Sub-group
Kaplan-Meier analyses of PFS and OS according to age,
ECOG PS and duration of response to frontline therapy are
displayed in Fig 2.
PFS and OS were explored in a univariable non-stratified
Cox regression model by baseline characteristics. Older age,
ECOG PS ≥ 2, blastoid histology and shorter duration of
response to frontline therapy (progression within 24 months)
were significantly associated with inferior PFS (Table II). The
same pattern with OS was observed and raised lactate dehy-
drogenase (LDH) ratios and high white cell count (WCC)
were also adverse predictors.
Additional analyses of PFS and OS were performed using
important prognostic variables in a multivariable Cox regres-
sion model (Table III). The model revealed blastoid histology
to be a significant independent adverse predictor for PFS and
OS. Raised LDH and ECOG PS ≥ 2 were significant adverse
predictors of OS but not PFS, possibly due to reduced sam-
ple size as hazard ratios remained similar. Older age was not
independently associated with OS, again possibly limited by
sample size, but showed no association with PFS. Early pro-
gression of disease with frontline therapy was not indepen-
dently significant.
In 8 patients with CNS involvement at start of ibrutinib
the median PFS was 49 months (95% CI 00–105) and the
median OS 55 months (95% CI 29–82).
Table I. Baseline characteristics.
Characteristic
Median age, years (range) 73 (33–96)
Male (n = 211) 147 (70%)
Performance status (n = 193)
ECOG 0–1 147 (76%)
ECOG 2 36 (19%)
ECOG 3–4 10 (5%)
Lactate dehydrogenase ratio (n = 147)
<10 75 (51%)
≥10 72 (49%)
White cell count (n = 197)
<10 9 109/l 137 (70%)
≥10 9 109/l 60 (30%)
Simplified MIPI group (n = 142)
Low risk 19 (13%)
Intermediate risk 58 (41%)
High risk 65 (46%)
CNS disease (n = 211)
Absent 203 (96%)
Present 8 (4%)
Histology* (n = 205)
Non-blastoid 176 (86%)
Blastoid 29 (14%)
Ki67 immunohistochemistry* (n = 141)
<30% 65 (46%)
≥30% 76 (54%)
Stage* (n = 208)
I–II 14 (7%)
III–IV 194 (93%)
Frontline therapy (n = 211)
R-CHOP 66 (31%)
High-dose cytarabine based regimen 60 (28%)
R-Bendamustine 45 (21%)
Chlorambucil R 15 (7%)




Stem cell transplant consolidation
Autologous HSCT 50 (24%)
Allogeneic HSCT 3 (1%)
CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone;
CNS, central nervous system; ECOG, Eastern Cooperative Oncology
Group performance status; HSCT, haematopoietic stem cell trans-
plant; MIPI, mantle cell lymphoma international prognostic index;
R, rituximab; VR-CAP, bortezomib, rituximab, cyclophosphamide,
doxorubicin, prednisolone. *recorded at diagnosis; ¥rituximab,
cyclophosphamide, vincristine, prednisolone n = 3; R-CHOP plus
ifosfamide, etoposide and epirubicin n = 2; prednisolone, mitox-
antrone, cyclophosphamide, etoposide, bleomycin, vincristine n = 1;
etoposide n = 1.
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Frontline
211 117 57 25 2 0
211 136 102 67 47 34
Number at risk
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Median PFS 17·8 months (95% CI 13·3-22·2)
Frontline
Median PFS 21·5 months (95% CI 15·5-27·4)
211 137 68 33 6 1
Number at risk












Fig 1. Progression free survival (PFS) with ibrutinib versus PFS with frontline therapy (A) and Overall Survival (B).
123 78 40 20 2 0
88 39 17 5 0 0
Number at risk
Age <75 years
Median PFS 20·5 months (95% CI 15·5-25·5)
Age ≥75 years
Median PFS 11·0 months (95% CI 7·4-14·6)
P = 0·045
123 107 56 25 5 1





Median OS 32.3 months (95% CI 20.0-44.6)
Age ≥75 years
Median OS 16.3 months (95% CI 10.2-22.3)
P = 0.002
147 91 46 17 2 0
46 18 8 4 0 0
ECOG 0 + 1
ECOG 2+
Number at risk
ECOG 0 + 1
Median PFS 20·6 months (95% CI 15·9-25·3) 
ECOG 2+
Median PFS 8·9 months (95% CI 5·0-12·9)
P = 0·003
147 107 56 25 5 1
46 20 8 5 1 0
ECOG 0 + 1
ECOG 2+
Number at risk
ECOG 0 + 1
Median OS 33·6 months (95% CI 23·9-43·3) 
ECOG 2+
Median OS 10·2 months (95% CI 6·0-14·4)
P = <0·001
102 69 32 14 1 0




Frontline POD ≥24 months
Median PFS 21·6 months (95% CI 16·0-27·1) 
Frontline POD <24 months
Median PFS 10·3 months (95% CI 5·7-14·8)
P = 0·003
102 82 37 16 4 1




Frontline POD ≥24 months
Median OS 33·6 months (95% CI 20·4-46·8) 
Frontline POD <24 months






































Fig 2. Progression free survival and overall survival stratified according to patient age (A,B), ECOG performance status (C,D) and duration of
response to frontline therapy (E,F).
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Ibrutinib dose reductions and discontinuation
Nine patients (4%) commenced ibrutinib at a dose less
than 560 mg o.d. because of frailty. Thirty patients (15%)
underwent 31 dose reductions during treatment. In 25
cases the indication involved clinician reported drug-related
adverse events including bleeding (5/31), cardiac (3/31)
and gastrointestinal events (3/31) (full details Table IV).
In total, 152 patients discontinued ibrutinib at data lock
with the majority due to progressive disease (100/152, 66%).
Other indications for treatment discontinuation included:
consolidation with alloHSCT 11% (17/152), drug-related
adverse event 7% (10/152), co-morbidities 4% (6/152), and
death whilst on therapy 12% (18/152) (Table IV). Causes of
death included: sepsis (5 cases), subdural haematoma (1
case), thrombotic stroke (1 case), pulmonary embolus (1
case), post-surgery complications (1 case), heart failure (1
case) and 8 were unknown.
For patients stopping ibrutinib for adverse events median age
at start of therapy was 78 years (range 68–89) and median dura-
tion of treatment was 12 months (range 1–28 months). For
patients who died whilst on ibrutinib the median age at start of
treatment was 78 years (range 68–93) and ECOG PS was ≥2 in
60% (9/15). The median duration of ibrutinib at time of death
was 9 months (range 1–44 months).
Of the 17 patients stopping ibrutinib for consolidation
with alloHSCT, the median age was 55 years (range 33–65).
There were nine PFS events and seven deaths during follow-
up with the median PFS 340 months (95% CI 88–591) and
24-month overall survival 566%.
Table II. Univariable Cox regression analysis of PFS and OS according to baseline characteristics.
Characteristics Patients, n
PFS OS
HR (95% CI) P value HR (95% CI) P value
Age (for an increase of 10 years) 211 121 (103–142) 0020 138 (115–165) 0001
ECOG PS 0 + 1 vs. ≥2 147 vs. 46 056 (038–083) 0003 041 (027–062) <0001
LDH ratio <10 vs. ≥10 75 vs. 72 069 (047–103) 0066 054 (035–084) 0006
WCC, 9109/l <10 vs. ≥10 137 vs. 60 079 (055–114) 0209 066 (045–097) 0036
sMIPI risk Low + Int. vs. High 77 vs. 65 069 (046–103) 0066 055 (035–085) 0007
Histology Blastoid vs.
non-blastoid
29 vs. 176 226 (147–347) <0001 243 (154–381) <0001
Ki67 <30% vs. ≥30% 64 vs. 77 074 (048–112) 0155 083 (052–131) 0412
Frontline therapy
HD cytarabine Yes vs. no 60 vs. 151 087 (061–125) 0451 069 (046–104) 0075
HSCT consolidation Yes vs. no 53 vs. 158 075 (051–110) 0143 060 (039–094) 0025
Response to frontline
Early PODs Yes vs. no 109 vs. 102 165 (118–231) 0003 181 (125–262) 0002
Bold value indicates statistical significance of P values =<0.05
CI, confidence interval; CR/CRu, complete response/complete response unconfirmed; ECOG PS, Eastern Cooperative Oncology Group
performance status; Early POD, progression of disease within 24 months; HD, high-dose; HR, hazard ratio; HSCT, haematopoietic stem cell
transplant; Int., intermediate; OS, overall survival; PFS, progression-free survival; PR, partial response; sMIPI, simplified mantle cell lymphoma
international prognostic index.
Table III. Multivariable Cox regression analysis of PFS and OS according to baseline characteristics.
Characteristics Patients, n
PFS OS
HR (95% CI) P value HR (95% CI) P value
Age (for an increase of 10 years) 140 104 (083–130) 0741 124 (096–160) 0108
ECOG PS 0 + 1 vs. ≥2 110 vs. 30 065 (040–106) 0085 058 (034–098) 0042
LDH ratio <10 vs. ≥10 71 vs. 69 072 (047–111) 0136 053 (033–086) 0010
WCC, 9109/l <10 vs. ≥10 95 vs. 45 0717 (046–112) 0143 062 (038–101) 0053
Blastoid histology Yes vs. No 20 vs. 120 295 (172–507) <0001 340 (189–614) <0001
Frontline early POD Yes vs. No 66 vs. 74 148 (096–226) 0073 119 (074–191) 0476
Bold value indicates statistical significance of P values =<0.05
CI, confidence interval; Early POD, progression of disease within 24 months; ECOG PS, Eastern Cooperative Oncology Group performance
status; HR, hazard ratio; LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-free survival; WCC, white cell count.
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Post-ibrutinib outcomes in patients progressing through
ibrutinib
Baseline characteristics of patients discontinuing ibrutinib
due to progressive disease (n = 100) are listed in Table V. Of
the 98 patients with available data, 56 patients (57%)
received no additional systemic therapy after ibrutinib cessa-
tion and 42 patients (43%) received at least one additional
course of treatment. Baseline characteristics of these two
groups showed distinct trends. In a univariable analysis,
younger age, ECOG PS 0–1 at start of ibrutinib and non-
blastoid histology were strongly associated with the use of
post-ibrutinib therapy (Table V). Patients who received post-
ibrutinib systemic therapy tended to have better treatment
responses versus patients who did not receive post-ibrutinib
therapy, as evidenced by median PFS to frontline therapy
(165 months, 95% CI 99–230, vs. 105 months, 95% CI
87–122, log-rank P = 0028) and median PFS with ibrutinib
(117 months, 95% CI 73–161, vs. 34 months, 95% CI
18–50, P = 0006).
At data-lock 81 of 100 patients with progressive disease
had died. The median follow-up from date of ibrutinib dis-
continuation for survivors was 13 months (range 0–
29 months). The median OS from ibrutinib discontinuation
was 14 months (95% CI 06–22). Patients receiving further
systemic therapy had significantly improved outcomes (me-
dian post-ibrutinib OS 116 months, 95% CI 68–165, vs.
04 months, 95% CI 02–05, P=<0001) (Fig 3A).
Post-ibrutinib systemic therapy consisted of rituximab,
bendamustine, cytarabine (R-BAC) in 50% (21/42), ritux-
imab, cyclophosphamide, doxorubicin, vincristine, pred-
nisolone (R-CHOP) in 12% (5/42), rituximab, bendamustine
(R-B) in 10% (4/42), and assorted chemotherapy combina-
tions in 24% (10/42). Five patients who received R-BAC were
consolidated with alloHSCT, and one patient who received
R-B, transplanted in first remission, was consolidated with
donor lymphocyte infusion. Five patients received fourth line
therapy: 2 received R-BAC, one patient received lomustine,
etoposide, chlorambucil, dexamethasone (DECC), one
received fludarabine and one patient received a bispecific
monoclonal antibody on clinical trial.
In total, 23 patients with a median age 68 years (range
57–77) received post-ibrutinib R-BAC. This group was
younger than patients receiving other post-ibrutinib therapy
but had similar responses to ibrutinib (Table SI). Those
receiving R-BAC displayed a trend toward improved survival
compared to patients receiving other therapies (median post-
ibrutinib OS 140 months, 95% CI 81–198, vs. 36 months,
95% CI 26–45, P = 006) (Fig 3B).
Discussion
The pooled trial analysis of 370 patients reported by Rule
et al.5 highlighted a significant benefit in PFS and OS for
patients with MCL receiving ibrutinib at first relapse com-
pared to later relapse and our study is the first to evaluate
how real-world outcomes support these data. It is notable
that despite representing an unselected group, the response
rates reported in our study appear equivalent to those in the
pooled analysis. The median PFS is modestly reduced
(178 months vs. 254 months) but exceeds the outcomes
observed for patients receiving ibrutinib at later relapses on
clinical trials. The median OS, however, demonstrates
marked divergence (239 months vs. 616 months). A dis-
crepancy most attributable to marked differences in patient
demographics, particularly age and performance status (me-
dian age 73 years vs. 67 years; ECOG PS ≥ 2 in 24% vs.
6%).
Comparison with historical real-world data from the UK
highlights the positive impact of ibrutinib. The Haematologi-
cal Malignancies Research Network (HMRN) registry, cover-
ing a UK-based population of 4 million, observed survival
trends in patients diagnosed with MCL between 2004 and
2015.11 Of patients receiving second-line therapy, the median
OS from start of treatment was only 10 months. Poor
Table IV. Ibrutinib dose reductions during therapy and indications
for stopping therapy.
Indications Number (%)
Dose reductions during therapy (n = 207)
All indications 31 (15%)
Drug-related adverse event 25 (12%)
Bleeding 5
Haematological adverse event 4
Cardiac adverse event 3







Drug interaction 1 (<1%)
Frailty 3 (1%)
Unknown indication 2 (1%)
Indications for stopping ibrutinib (n = 151)
Progressive disease 100 (66%)
Allogeneic HSCT 17 (11%)
Drug-related adverse event 10 (7%)
Gastrointestinal adverse event 3
Cardiac adverse event 2
Bleeding 1
General toxicity 1




Other cancer diagnosis 2 (1%)
Medical co-morbidities 1 (<1%)
Death during treatment 18 (12%)
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outcomes for older patients were notable, with median OS
from date of diagnosis only 19 months for those aged
≥70 years. The high proportion of older patients in our study
indicates widespread use of ibrutinib in the UK and the
median OS from start of ibrutinib of 16 months for those
age ≥75 years appears to represent an important break-
through.
It has been observed that early POD following frontline
therapy in younger MCL patients is an independent predic-
tor for inferior survival at time of relapse, and this cohort
had superior outcomes receiving second-line ibrutinib com-
pared to chemotherapy.12–13 In our study early POD was
associated with inferior PFS and OS, but this association was
lost in multivariable analysis indicating in our more hetero-
geneous population other variables were more predictive of
survival.
Despite an older patient population tolerance to ibrutinib
appears good, with discontinuation linked to drug-related
adverse events similar to those reported in clinical trials. This
is in contrast to real-world evidence from the United States
where 21% of patients stopped ibrutinib due to drug-related
adverse events.14 The difference may relate to the restricted
availability of effective alternative therapy in the UK, particu-
larly other BTK inhibitors, which encourages clinicians to
manage toxicity without stopping ibrutinib. The death rate
during ibrutinib therapy was high relative to trials but simi-
lar to real-world data for ibrutinib in chronic lymphocytic
leukaemia and likely relates to competing risks of death, with
advanced age and poor performance status noted in many
affected patients.15
The post-ibrutinib outcomes reported in our study
require careful consideration. That only 43% of patients









(n = 42) OR (95% CI) P value
Median age, years (range) 73 (44–92) 74 (46–92) 70 (44–85) 094 (089–098) 0011
At start of ibrutinib
ECOG PS ≥ 2 26 of 91 (29%) 21 of 52 (40%) 4 of 37 (11%) 018 (005–058) 0004
Blastoid histology 24 of 100 (24%) 18 of 56 (32%) 5 of 42 (12%) 029 (010–085) 0024
CNS involvement 6 of 100 (6%) 5 of 56 (9%) 1 of 42 (2%) 025 (003–221) 0212
sMIPI high risk 37 of 74 (50%) 23 of 41 (56%) 12 of 31 (39%) 049 (019–128) 0146
Response to prior therapy
Frontline early POD 67 of 100 (67%) 41 of 56 (73%) 26 of 42 (62%) 060 (025–140) 0235
Frontline median PFS, mo. 135 (85–186) 105 (87–122) 165 (99–230)
ORR to ibrutinib (CR/CRu) 53% (18%) 51% (10%) 57% (29%)
Median PFS to ibrutinib, mo. 67 (49–84) 34 (18–50) 117 (73–161)
Bold value indicates statistical significance of P values =<0.05.
CNS, central nervous system; CR, complete response; Early POD, progression of disease within 24 months; ECOG PS, Eastern Cooperative
Oncology Group performance status; ORR, overall response rate; PFS, progression-free survival; sMIPI, simplified mantle cell lymphoma
international prognostic index. *Post-ibrutinib management in 2 patients unknown.
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Fig 3. Post-ibrutinib overall survival for patients progressing on ibrutinib: received further systemic therapy versus no further systemic therapy
(A) and received R-BAC versus alternative systemic therapies (B).
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progressing on ibrutinib received further systemic therapy
appears low, especially compared to 70% in the cohort
reported by Martin et al.8 The reasons for this discrepancy
likely relate to the older patient population and limited
treatment options available compared to a cohort treated
primarily at academic centres with access to clinical trials.
Of interest, the rate of subsequent treatment in our study is
similar to that reported in the HMRN registry, where only
39% of MCL patients received third line therapy, suggesting
the general availability of ibrutinib has not altered this UK
approach. In addition, with this historical HMRN cohort,
where 16% received ibrutinib at third line or later, the
median OS from the start of third line was only 7 months,
indicating that the poor outcomes observed in this setting
are not specific to ibrutinib. Promisingly, patients who
received post-ibrutinib R-BAC in our study showed a strong
trend to improved OS, a finding consistent with a recent
study illustrating high response rates to R-BAC post BTK
inhibitor (ORR 83%, CR/CRu 60%).16
It was not possible to access data on ibrutinib use at
national level but as our series provides a balanced represen-
tation of academic centres and DGHs results should reflect
all institutions where the drug is prescribed in the UK. Steps
taken to mitigate inherent bias of retrospective methodology
mean the extent of adverse events were only partially
explored and inconsistent timing of response assessments
mean data was not suitable for time-dependent analysis and
should be interpreted carefully alongside prospective data.
PFS data were similarly hindered but as the kinetics of pro-
gression in MCL is invariably rapid and easy to determine
we believe results are representative of the real-world.
These limitations notwithstanding our findings consolidate
the central role of ibrutinib in MCL therapy and support use
at first relapse. However, with a third of patients progressing
within 12 months and no survival plateau improved strate-
gies are required. Studies have assessed giving ibrutinib
alongside complimentary novel agents including lenalido-
mide, umbralisib and palbociclib.17–19 To date, these have
reported increased toxicity without an obvious benefit in
outcome, but the combination with the BCL2 inhibitor vene-
toclax appears promising with phase II study reporting a CR
rate of 72% and median PFS of 29 months.20–21 A phase III
trial comparing venetoclax plus ibrutinib with ibrutinib
monotherapy is ongoing (SYMPATICO, NCT03112174). Sec-
ond generation BTK inhibitors acalabrutinib and zanubruti-
nib have FDA approval in relapsed MCL and whilst evidence
of improved efficacy is lacking, reduced off target effects offer
potential for improved tolerability.22
MCL progressing through ibrutinib continues to represent
a major clinical challenge. Our results further establish a role
for R-BAC, but achieving durable responses appears depen-
dent on consolidation with cellular therapies. This has tradi-
tionally been restricted to a minority of younger patients
able to tolerate alloHSCT23 but the impressive results for chi-
meric antigen receptor T-cell therapy in post BTK inhibitor
MCL suggest this approach may soon be superseded.24 How-
ever, it is not established if early results will translate into
long-term disease-free survival and trial data may be difficult
to replicate in real-world populations.
In summary, our study confirms the clinical benefit of
ibrutinib monotherapy for MCL at first relapse. Comparison
with historical data indicates a particular benefit in older
patients and overall tolerability appears to be good. In the
post-ibrutinib setting, OS is relatively short but treatment
with R-BAC in select patients is promising. Developing ibru-
tinib combination therapies for high risk patients and more
effective salvage therapies remains a priority.
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